ArticleClinical transplantation2026
A Snapshot View of Sarcopenia and Frailty Status in Kidney Transplant Recipients.
Article in Clinical transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSarcopenia, defined as loss of skeletal muscle mass and function, often progresses to frailty and is associated with unfavorable post-transplant outcomes. Frailty is characterized by diminished physiological capacity and increased vulnerability. On the other hand, kidney transplantation is associated with lower mortality rates and improved quality of life. The aim of this study is to determine the prevalence of frailty status using two different methods in kidney transplant (KT) recipients, to investigate the relationship between sarcopenia and frailty status, and to identify factors that influence both conditions.
methodsWe included 123 KT recipients who were admitted to the transplant outpatient clinic between March 2024 and July 2024. EWGSOP2 criteria were used to diagnose sarcopenia. Modified Fried's Frailty Phenotype criteria and FRAIL scale were used to assess frailty.
resultsMean age was 49±12 years and 45.5% were female. Overall, 32.5% and 4.9% of patients were identified as probable sarcopenic and sarcopenic, consecutively. The number of patients with deceased transplantation was higher in sarcopenic patients (p = 0.004). When grouped according to Modified Fried's Frailty Phenotype 41.5% of patients were prefrail and 4.1% were frail. According to FRAIL scale, 28.5% of participants were prefrail, and 3.3% were frail. Two scales showed substantial agreement. Serum phosphorus was higher in the frail and prefrail patient groups according to both frailty scales compared to robust group (p<0.001, p = 0.04).
conclusionsPre-frailty and sarcopenia are common in KT recipients and are associated with higher serum phosphorus. Notably, sarcopenia was linked to having a deceased donor transplantation, underscoring the importance of targeted screening and management in this population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.